News & Events

Major Milestone! US Approves Phage Therapy for Refractory Antimicrobial-Resistant Infections

2023-04-24

Major Milestone! US Approves Phage Therapy for Refractory Antimicrobial-Resistant Infections

Executive Summary: FDA approvals and clinical expansions of bacteriophage therapeutics signal a transformative global paradigm shift toward biological alternatives to conventional chemical antibiotics.

Published by: Shandong New-Line Biotechnology Co., Ltd. (New-Line Bio)

For international inquiries, please visit our official website: en.phages.cn or contact: info@phages.cn

Previous: Unveiling of the "Phage Industry Research Institute" Opens a New Chapter in Antibiotic Replacement Next: Corporate Visit | Senior Leadership Delegation from CP Chia Tai Group Visits Shandong New-Line Bio

Product classification

Address：31-3-102, Jinke Smart Technology City, 200m in the south of the intersection between Changsong Road and Chunyuan Road, Weicheng District, Weifang City, Shandong Province
Contact：Miss Cao
Tel.：+86-536-2201616
Website：en.phages.cn

Data indicated in product descriptions originates from R&D laboratory test data and clinical trial data. For specific application protocols, please combine with actual on-site conditions and consult professional technical personnel.